Health Care Innovation
Commentary
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Wayne Winegarden
February 24, 2020
Commentary
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Wayne Winegarden
February 24, 2020
Commentary
Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s
The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
Sally C. Pipes
January 31, 2020
Blog
Newsom’s ‘Bold’ Plan on Prescription Drugs Won’t Really Help Patients, Lower Drug Costs
In a state where the private sector continues to be marginalized in favor of more government, Gov. Gavin Newsom has plans for California to set up a generic drug label of its own. It would be the first state in the country to go into the pharmaceutical business, and will ...
Kerry Jackson
January 27, 2020
Commentary
Price Controls Impose High Costs On Patients
Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Wayne Winegarden
January 23, 2020
Drug Pricing
Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News
Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Pacific Research Institute
January 23, 2020
Drug Pricing
Wayne Winegarden – Why the Pelosi and Newsom Approaches to Prescription Drugs Won’t Really Help Patients
Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, breaks down recently-proposed plans in Washington and Sacramento that emphasize price caps and more government control to address prescription drug prices. He discusses the conclusions of his new study on America’s drug pricing challenge, which makes the case ...
Pacific Research Institute
January 13, 2020
Blog
Lies, Damn Lies, and Drug Price Increases
As each new year begins, the increases in the list prices of drugs are announced. And, following these announcements, the political class complains that something must be done. This year, following the price announcements, Speaker Nancy Pelosi tweeted “Enough is enough” while Senator Grassley emphasized that a “call to action” ...
Wayne Winegarden
January 8, 2020
Drug Pricing
NEW STUDY shows that Reforming Supply Chain & Drug Pricing System Will Lower Health Care Costs
As Washington pushes for price caps and government controls to address prescription drug prices, a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute argues that reforming the complex drug supply chain and ending the current drug pricing system that overcharges ...
Wayne Winegarden
January 8, 2020
Commentary
America’s Critical Medical Device Industry Gets A Needed Tax Cut
Medical devices may not be as glamorous as blockbuster drugs, but they include some of the genuine miracles of modern medicine: pacemakers, artificial joints, replacement heart valves, scanners, and cancer radiation-therapy machines. The U.S. has been the global leader in medical devices, one of the few major industries that both ...
Henry Miller, M.S., M.D.
December 26, 2019
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s
The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
Newsom’s ‘Bold’ Plan on Prescription Drugs Won’t Really Help Patients, Lower Drug Costs
In a state where the private sector continues to be marginalized in favor of more government, Gov. Gavin Newsom has plans for California to set up a generic drug label of its own. It would be the first state in the country to go into the pharmaceutical business, and will ...
Price Controls Impose High Costs On Patients
Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News
Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Wayne Winegarden – Why the Pelosi and Newsom Approaches to Prescription Drugs Won’t Really Help Patients
Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, breaks down recently-proposed plans in Washington and Sacramento that emphasize price caps and more government control to address prescription drug prices. He discusses the conclusions of his new study on America’s drug pricing challenge, which makes the case ...
Lies, Damn Lies, and Drug Price Increases
As each new year begins, the increases in the list prices of drugs are announced. And, following these announcements, the political class complains that something must be done. This year, following the price announcements, Speaker Nancy Pelosi tweeted “Enough is enough” while Senator Grassley emphasized that a “call to action” ...
NEW STUDY shows that Reforming Supply Chain & Drug Pricing System Will Lower Health Care Costs
As Washington pushes for price caps and government controls to address prescription drug prices, a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute argues that reforming the complex drug supply chain and ending the current drug pricing system that overcharges ...
America’s Critical Medical Device Industry Gets A Needed Tax Cut
Medical devices may not be as glamorous as blockbuster drugs, but they include some of the genuine miracles of modern medicine: pacemakers, artificial joints, replacement heart valves, scanners, and cancer radiation-therapy machines. The U.S. has been the global leader in medical devices, one of the few major industries that both ...